Mixed
Achieving a body weight loss of 5% or greater within 12 weeks of initiating SGLT2 inhibitor treatment significantly reduces the risk of new-onset atrial fibrillation in patients with type 2 diabetes.
If you are taking an SGLT2 inhibitor for Type 2 Diabetes, aim for a body weight loss of at least 5% within the first 3 months. This specific threshold is associated with a significantly lower risk of developing atrial fibrillation compared to those who do not lose weight. However, this weight loss benefit did not extend to reducing heart failure hospitalizations or other major cardiovascular events in this study.
Compared with those without BW loss after SGLT2i treatment, AF risk significantly decreased with a BW loss of ≥ 5.0% (adjusted hazard ratios [95% confidence intervals]: 0.39[0.22–0.68]).
Why this rating
Large real-world observational database (n=10,237) with multivariate adjustment, though not a randomized controlled trial.
Source
The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor
Yi‐Hsin Chan et al. · Cardiovascular Diabetology · 2021
DOI 10.1186/s12933-021-01285-8
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →